Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) was up 6.4% on Monday . The stock traded as high as $12.88 and last traded at $12.77. Approximately 27,430 shares traded hands during trading, a decline of 90% from the average daily volume of 270,449 shares. The stock had previously closed at $12.00.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on MAZE. TD Cowen upgraded Maze Therapeutics to a "strong-buy" rating in a research note on Tuesday, February 25th. Leerink Partners initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $28.00 price target for the company. Leerink Partnrs upgraded Maze Therapeutics to a "strong-buy" rating in a report on Tuesday, February 25th. JPMorgan Chase & Co. initiated coverage on shares of Maze Therapeutics in a research report on Tuesday, February 25th. They set an "overweight" rating and a $30.00 target price on the stock. Finally, Guggenheim began coverage on shares of Maze Therapeutics in a report on Tuesday, February 25th. They set a "buy" rating and a $19.00 price objective for the company. Three research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $25.67.
View Our Latest Report on MAZE
Maze Therapeutics Price Performance
About Maze Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.
See Also
Before you consider Maze Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.
While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
